-
公开(公告)号：US20240075061A1
公开(公告)日：2024-03-07
申请号：US18065301
申请日：2022-12-13
发明人： Wensheng Wang , Dongqi Chen , Chengfei Pu , Zhao Wu , Lei Xiao , Zhiyuan Cao , Le Tian
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C12Q1/6886
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4622 , A61K39/4631 , A61K39/464412 , A61K39/464454 , A61P35/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.
-
公开(公告)号：US20220105134A1
公开(公告)日：2022-04-07
申请号：US17490582
申请日：2021-09-30
发明人： Zhiyuan Cao , Lei Xiao , Yuzhe Peng , Wei Ding , Wensheng Wang
IPC分类号： A61K35/17 , C07K14/47 , C07K14/725
摘要： The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
-
公开(公告)号：US12043654B2
公开(公告)日：2024-07-23
申请号：US17331289
申请日：2021-05-26
发明人： Lei Xiao , Xiaogang Shen , Wensheng Wang , Dongqi Chen , Beibei Jia , Chengfei Pu , Le Tian
IPC分类号： C07K16/40 , A61K35/17 , A61P35/00 , C07K14/725 , A61K38/00
CPC分类号： C07K14/7051 , A61K35/17 , A61P35/00 , C07K16/40 , A61K38/00 , C12Y406/01002
摘要： The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).
-
公开(公告)号：US11944645B2
公开(公告)日：2024-04-02
申请号：US17490582
申请日：2021-09-30
发明人： Zhiyuan Cao , Lei Xiao , Yuzhe Peng , Wei Ding , Wensheng Wang
IPC分类号： A61K35/17 , C07K14/47 , C07K14/725
CPC分类号： A61K35/17 , C07K14/4702 , C07K14/7051
摘要： The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
-
公开(公告)号：US20220348682A1
公开(公告)日：2022-11-03
申请号：US17270571
申请日：2019-08-29
发明人： Lei Xiao , He Sun , Zhiyuan Cao , Wensheng Wang , Chengfei Pu , Li Mao
IPC分类号： C07K16/30 , C07K14/725 , A61K47/68
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
-
公开(公告)号：US20210230308A1
公开(公告)日：2021-07-29
申请号：US17220387
申请日：2021-04-01
发明人： Lei Xiao , He Sun , Zhiyuan Cao , Wensheng Wang , Chengfei Pu , Li Mao
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
-
公开(公告)号：US20240024476A1
公开(公告)日：2024-01-25
申请号：US18260376
申请日：2022-01-06
发明人： Chengfei Pu , Zhiyuan Cao , Xiaogang Shen , Wensheng Wang , Beibei Jia , Dongqi Chen , Xiaoqiang Xu , Xudong Tang , Wei Ding , Xianyang Jiang , Yuzhe Peng , Guiting Han , Le Tian , Zhao Wu , Lei Xiao
IPC分类号： A61K39/00 , C07K14/725 , C12N5/0783 , C07K16/30 , C07K16/28 , C07K16/18 , C07K16/40 , A61P35/00
CPC分类号： A61K39/4631 , C07K14/7051 , C12N5/0636 , C07K16/3023 , C07K16/303 , C07K16/2875 , C07K16/2803 , C07K16/28 , C07K16/2851 , C07K16/18 , C07K16/40 , A61P35/00 , A61K39/4611 , A61K39/4644 , A61K39/464474 , A61K39/464417 , A61K39/464402 , A61K39/464458 , A61K39/464411 , C07K2319/03 , C07K2319/33 , C07K2317/622 , A61K2239/13 , C07K2317/31
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.
-
公开(公告)号：US20210371492A1
公开(公告)日：2021-12-02
申请号：US17331289
申请日：2021-05-26
发明人： Lei Xiao , Xiaogang Shen , Wensheng Wang , Dongqi Chen , Beibei Jia , Chengfei Pu , Le Tian
IPC分类号： C07K14/725 , A61K35/17 , C07K16/40 , A61P35/00
摘要： The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).
-
公开(公告)号：US11161913B2
公开(公告)日：2021-11-02
申请号：US17220387
申请日：2021-04-01
发明人： Lei Xiao , He Sun , Zhiyuan Cao , Wensheng Wang , Chengfei Pu , Li Mao
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
-
公开(公告)号：US20210024890A1
公开(公告)日：2021-01-28
申请号：US16936874
申请日：2020-07-23
发明人： Chengfei Pu , Wensheng Wang , Dongqi Chen , Lei Xiao
IPC分类号： C12N5/0783 , C07K14/705 , C07K16/28 , C07K14/725
摘要： The present disclosure describes a method of producing T cells exhibiting an enhanced memory T cell phenotype, the method comprising: modulating a population of T cells to enhance the expression and/or function of high mobility group protein Y (HMGY). In embodiments, the method may include introducing a polynucleotide encoding HMGY into a population of T cells, wherein expression of HMGY is higher in the population of T cells as compared to a population of T cells that are not introduced with the polynucleotide, and the memory T cell phenotype of the population of T cells is enhanced as compared to T cells that are not introduced with the polynucleotide. In embodiments, the method can also include introducing a polynucleotide encoding one or more genes associated with HMGY, for example, upstream or downstream of the signaling pathway associated with HMGY and/or a transcription factor associated with HMGY.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
